EMOSIS reinforces its Intellectual Property and scientific expertise

The French innovative Medical Device start-up Emosis, specializing in cytomolecular diagnostics of thrombosis and hemostasis disorders, is reinforcing its intellectual property on HIT Confirm®, Emosis first test kit which was recently launched in Europe
(CE Mark).

The company was granted a US patent “Platelet Analysis System” (US10, 012,658 B2), and the PCT of the patent “Heparin-induced thrombocytopenia test” (PCT/IB2018/052179) was recently published.

Heparin-induced thrombocytopenia (HIT) is a potentially lethal disorder caused by heparin,  the most prescribed injectable anticoagulant worldwide, and the patent covers a rapid, on  demand, functional test to confirm the diagnosis of
that condition.

Rapid and accurate diagnosis of HIT is of critical clinical importance because of an initial 6% daily risk of thromboembolism, amputation and death, while misdiagnosis. In contrast, unnecessarily exposes patients without HIT to costly alternative
anticoagulants and their attendant 1% daily risk of major bleeding (Cuker 2014).

Dr. Frederic Allemand, Emosis CEO, declared: “These patents reinforce Emosis intellectual property arsenal and confirm the innovativeness of the cytomolecular approach in diagnosing hemostasis and thrombosis disorders.